CLINICAL TRIAL ON TERAPEUTIC EFFICACY, TOLERABILITY AND SAFETY OF PERORAL SOLUTIONS VARUMIN® 1 AND 2 (INTER-EVROGENEKS) IN A COMBINED TREATMENT WITH POLYVITAMIN – ANTIOXIDATIVE THERAPY IN PATIENTS WITH BIOLOGICALY (PCR) DETECTED HPV INFECTION OF HIGH-RISK TYPE, WITH OR WITHOUT BIOPTICALY VERIFIED CIN I

Final Results ___________________________________________________________________

Varumin® is new hope for all MULTIPLE SCLEROSIS (MS) patients.

One small, but still significant study made some time ago, undoubtedly has proven that immuno-modulatory effect of Varumin® acts hepful in treatment of this ilness.

"Inter-evrogeneks" goes on with promotion of the first product ever, which managed complete elimination of presence of all signs characteristical for MS.

read the PDF ____________________________________________________________________

Topic of the study is: Clinical examination of therapeutical efficacy, tolerance and safety of Varumin® in patients with molecular biology (PCR) proven HPV infection typed with high risk, with and without bioptical proven CIN. Until now, results are in favur of expectations.
<-- Study protocol (Macedonian language)

This first statistical cut is the beginning of wave that will give scientific approval to all indications claimed about Varumin® during all these years. Varumin® therapy will be first-choice therapy in all conditions characterized with compromised immunity.
<-- read about first results

____________________________________________________________________

Expert's report: WHO expert Sibin Ilic, PhD, MD, for Varumin®.

<-- View the report